BIIB Maintains by Wells Fargo -- Price Target Raised to $310

gurufocus.com · 2026-10-20

Biogen Inc. Analyst Rating Update On October 12, 2026, Wells Fargo announced that it is maintaining its Overweight rating for Biogen (BIIB), while raising th

TickrTrends take: Wells Fargo's price target increase to $310 for BIIB comes as TickrTrends currently assesses the stock as overvalued within the Healthcare sector. A valuation-focused reader should monitor whether this analyst action signals a shift in market consensus that could narrow the gap between current market pricing and intrinsic value estimates, or whether the stock remains stretched relative to fundamental measures. The divergence between analyst price targets and valuation models in the Healthcare space warrants continued attention to earnings reports and pipeline developments that could inform whether the overvaluation thesis holds.

Read the full story at gurufocus.com →